The Glimins In The Treatment Of Type 2 Diabetes

MURAT BAŞ, CEVDET DURAN

  • Year : 2017
  • Vol : 33
  • Issue : 1
  •  Page : 19-21
The prevalence of type 2 diabetes is increasing world wide and it is estimated to rise from 382 million today to 582 million by 2035. Although there are a number of therapies currently avaible to treat diabetes mellitus, glycemic control rates remain poor. Imeglimin, the first in a new-tetrahydrotriazine-containing class of oral antidiabetic agents and it has been shown to decrease hepatic glucose production, increase glucose uptake in skeletal tissue and improve insulin secretion in response to glucose. In this text, the efficacy and safety of imeglimin in the treatment of type 2 diabetes are reviewed.
Cite this Article As :

Download Citation: Endnote/Zotero/Mendeley (RIS) RIS File

Download Citation: BibTeX BibTeX File

Description : None of the authors, any product mentioned in this article, does not have a material interest in the device or drug. Research, not supported by any external organization. grant full access to the primary data and, if requested by the magazine they agree to allow the examination of data.
The Glimins In The Treatment Of Type 2 Diabetes
, Vol. 33 (1)
Received : 23.08.2015, Accepted : 23.08.2015, Published Online : 13.08.2018
Selçuk Tıp Dergisi
ISSN:1017-6616;
E-ISSN:2149-8059;